

## **Clinical Appropriateness Guidelines**

# Genetic Testing for Heredity Cardiac Disease

**EFFECTIVE OCTOBER 14, 2017**



8600 West Bryn Mawr Avenue  
South Tower - Suite 800 Chicago, IL 60631  
[www.aimspecialtyhealth.com](http://www.aimspecialtyhealth.com)

Appropriate.Safe.Affordable  
© 2017 AIM Specialty Health  
2064-1017

## Table of Contents

Scope .....	3
Appropriate Use Criteria .....	3
Confirmation/Diagnostic Testing .....	3
Testing of Asymptomatic Individuals .....	3
Post-Mortem Testing.....	3
Long QT.....	4
Dilated Cardiomyopathy .....	5
Tests Not Clinically Appropriate .....	5
CPT Codes.....	5
Background .....	5
Long QT.....	6
Dilated Cardiomyopathy .....	6
Hypertrophic Cardiomyopathy.....	7
Brugada Syndrome .....	8
Short QT Syndrome .....	8
Atrial Fibrillation .....	8
Post-Mortem Testing.....	9
Professional Society Guidelines.....	9
Selected References.....	10
Revision History.....	11

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2017 Informed Medical Decisions, Inc. All Rights Reserved.

# Scope

This document addresses genetic testing for inherited arrhythmias and cardiomyopathies. Aortopathies and other connective tissue disorders with cardiac manifestations are NOT included in this document; see Genetic Testing for Single-Gene and Multifactorial Conditions Clinical Appropriateness Guidelines.

## Appropriate Use Criteria

### Confirmation/Diagnostic Testing

Confirmatory or diagnostic genetic testing for hereditary arrhythmias and cardiomyopathies is medically necessary when all of the following criteria are met:

- The individual is at risk for and/or has signs and symptoms of a hereditary cardiac disease
- The requested testing is as targeted as possible to a specific subset of genes related to the suspected condition (e.g. hypertrophic cardiomyopathy OR arrhythmogenic right ventricular cardiomyopathy/dysplasia)
- There are no additional relevant disease-specific criteria listed below

### Testing of Asymptomatic Individuals

Single-site genetic testing for a known familial deleterious or suspected deleterious mutation is medically necessary for the following indications:

- hypertrophic cardiomyopathy (HCM)
- catecholaminergic polymorphic ventricular tachycardia (CPVT)
- dilated cardiomyopathy (DCM)
- Brugada syndrome
- arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D)
- left ventricular non-compaction cardiomyopathy (LVNC)
- restrictive cardiomyopathy (RCM)

### Post-Mortem Testing

Post-mortem cardiac genetic testing of an individual with sudden unexplained death, whose first degree family member is a covered member, is reasonable in the following circumstances:

- When the autopsy reveals evidence for a *specific* underlying heritable cardiac condition (e.g. ARVC, HCM, DCM, RCM) AND all of the following criteria are met:
  - a. The corresponding targeted testing is ordered (e.g. HCM panel testing in cases where autopsy revealed evidence for HCM)
  - b. No other living relative has clinical evidence for the suspected condition (e.g. should a living relative have evidence for HCM, then testing for the living relative is recommended)

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2017 Informed Medical Decisions, Inc. All Rights Reserved.

- In ‘autopsy negative’ cases when all of the following criteria are met:
  - a. The deceased individual meets one of the following:
    - i. Age 40 years or younger at death
    - ii. Over 40 years at death and there is a documented family history of sudden death or cardiomyopathy
  - b. Cause for death remains unknown after completion of autopsy and toxicology testing (if completed)
  - c. The test requested is a single gene or targeted panel test for common genetic causes of sudden cardiac arrest/death and/or is as targeted as possible for the clinical indication

## Long QT

Genetic testing for long QT syndrome (LQTS) is medically necessary when the individual meets general criteria for hereditary cardiac genetic testing (above) and one of the following indications:

- confirmatory (i.e., diagnostic) testing when there is confirmed prolonged QT interval on electrocardiogram (ECG) or Holter monitor (i.e., corrected QT [QTc] interval of >470 msec [males] or >480 msec [females]), and an acquired cause has been ruled out
- predictive testing, when there is evidence in a first-degree relative of either of the following:
  - a history of prolonged QT interval on ECG or Holter monitor (i.e., corrected QT [QTc] interval of >470 msec [males] or >480 msec [females]) and the affected individual is not available for testing
  - sudden death of suspected cardiac diagnosis or near sudden death at age 40 or younger with no evidence of ischemia and no genetic testing was performed
- predictive testing for a known familial mutation for LQTS

## Dilated Cardiomyopathy

Targeted single gene (DES, LMNA, SCN5A) OR multi-gene DCM panel genetic testing is medically necessary when the general criteria for hereditary cardiac genetic testing (above) are met in addition to the following:

- individual has a clinical diagnosis of dilated cardiomyopathy (DCM)
- individual has significant cardiac conduction disease (first-, second- or third- degree block) and/or family history of premature cardiac death (<50 years) in a first- or second-degree relative
- individual is a candidate for an ICD

## Tests Not Clinically Appropriate

- Broad “multi-condition” panel testing (e.g. pan-cardio panel, arrhythmia panel) is not medically necessary.
- Genetic testing for short QT syndrome and atrial fibrillation is experimental, investigational and unproven.

# CPT Codes

The following codes are associated with the guidelines outlined in this document. This list is not all inclusive.

- |       |  |
|-------|--|
| 81413 | Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A. |
| 81414 | Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, catecholaminergic polymorphic ventricular tachycardia); duplication/deletion gene analysis panel, must include analysis of at least 2 genes, including KCNH2 and KCNQ1.   |
| 81439 | Inherited cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy) genomic sequence analysis panel, must include sequencing of at least 5 genes, including DSG2, MYPBC3, MYH7, PKP2, and TTN.                               |

# Background

Most forms of arrhythmias and cardiomyopathies are multifactorial. There are, however, several forms of Mendelian hereditary cardiac disease that cause severe and early-onset symptoms. The hereditary arrhythmias and cardiomyopathies are primarily diagnosed clinically and symptoms can be variable within the same family. Although genetic test results may not guide medical management for those with a clinical diagnosis, identification of a mutation can allow for detection of asymptomatic family members who might benefit from life-saving treatment. Most hereditary cardiac conditions are associated with multiple genes. Targeted panel testing is reasonable in most cases.

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2017 Informed Medical Decisions, Inc. All Rights Reserved.

## Long QT

Long QT syndrome (LQTS) is characterized by prolongation of the QT interval on electrocardiogram (ECG). LQTS disorders are considered channelopathies, or diseases that affect cardiac ion channels. This condition predisposes the individual to cardiac events and arrhythmias including: torsades de pointes, ventricular tachycardia, syncopal episodes, ventricular fibrillation and cardiac arrest.

LQTS is diagnosed by considering the clinical features, the family history, and the ECG findings of the patient. LQTS may be diagnosed when the prolongation of the QTc interval is >470 msec (males) or >480 msec (females) (Crotti 2008). The clinical features may range from minor symptoms such as dizziness, to more severe symptoms such as seizure, syncope and sudden death. Congenital LQTS will usually manifest before the age of 40 years, generally in childhood and adolescence with the age of onset associated with the genotype. Long-term management of LQTS may include lifestyle modification, beta-adrenergic blockers, permanent pacemaker implantation, and implantable cardioverter defibrillators.

At least 15 genes have been found to be associated with LQTS; however, mutations in 3 genes represent the most common causes: KCNQ1 (30-35%), KCNH2 (25-30%), and SCN5A (5-10%). Not all patients meeting clinical criteria for LQTS have detectable mutations in one of the known associated genes. The recommended testing approach includes either single gene sequencing or a multi-gene sequencing panel, which may be more cost effective given the multiple associated genes. Genetic screening may provide unique assistance to a family member with normal QT interval (Schwartz 2006), as at-risk individuals can be identified prior to the onset of symptoms.

## Dilated Cardiomyopathy

Dilated cardiomyopathy (DCM) is characterized by enlargement of the left ventricle of the heart and systolic impairment, in the absence of abnormal loading conditions or coronary artery disease sufficient to cause global systolic dysfunction (Haas 2015). The symptoms of DCM are similar to heart failure including shortness of breath, chest pain/tightness, fainting episodes and cardiac arrhythmias. The most serious complication of DCM is sudden, irregular heart rhythms that can be life threatening. Some individuals with DCM will have no symptoms throughout their lifetime.

DCM is a heterogeneous condition caused by ischemia, systemic disease (e.g. mitochondrial or muscular dystrophy), toxins, or infection. Twenty to 50 percent of cases of idiopathic DCM are inherited. DCM can be inherited as an X-linked, autosomal recessive or autosomal dominant condition. Autosomal dominant is the most common form of inherited DCM. There are at least 38 different genes known to cause DCM and many more genes implicated as associated with the condition. Genetic testing is available for multiple DCM genes, typically in large multi-gene panels. Genetic testing identifies a mutation in 22-50% of cases.

The 2011 HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies recommends comprehensive (testing all clinically available DCM genes) or targeted (LMNA and SCN5A) DCM genetic testing for patients with DCM and significant cardiac conduction disease (i.e. first, second or third degree heart block) and/or family history of premature unexplained death. In addition, they state that genetic testing can be useful for patients with familial DCM to confirm diagnosis, to recognize those who are at highest risk of arrhythmia and syndromic features, to facilitate cascade screening within the family and to help with family planning. Known familial mutation testing is recommended when a mutation has been identified in the family.

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2017 Informed Medical Decisions, Inc. All Rights Reserved.

Although genetic testing is useful in differentiating between familial versus isolated DCM, and therefore facilitates identification of at-risk family members, management for the individual affected with DCM typically does not change once a diagnosis of familial DCM is established. The one exception to this is when a LMNA mutation is identified. In individuals identified with a LMNA mutation requiring pacemaker placement (i.e. history of arrhythmia or known risk of arrhythmia), the use of a pacing ICD rather than a pacemaker has been recommended due to the risk of ventricular arrhythmias and sudden death (Meune 2006).

In families where a mutation is not yet identified, clinical screening (physical exam, echocardiogram, and ECG) for DCM is recommended for asymptomatic at-risk relatives yearly in childhood and every 1-3 years in adults (Journal of Cardiac Failure Vol. 15 No. 2 2009). If there is family history of early onset disease or family history of sudden death, increased frequency of screening may be more appropriate.

Once a familial mutation is identified, genetic testing for the known familial mutation in asymptomatic family members can differentiate between relatives who are at high risk of DCM and sudden death, versus relatives who did not inherit the familial mutation and for whom clinical screening is not warranted.

## Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is characterized by increased size of the left ventricle of the heart, typically caused by thickening of the walls of the heart. The symptoms of HCM can be variable, ranging from no symptoms to shortness of breath or irregular heart rhythms, or sudden death. The irregular heart rhythms can occur without warning and may be life threatening. HCM has a prevalence of 1/500 individuals, making it one of the most common cardiac genetic diseases. It is inherited as an autosomal dominant trait with reduced penetrance. Family history focused on history of sudden death and age of onset in family members can be helpful in risk stratification.

HCM is the most common cause of sudden death in athletes, accounting for 30% of cases of young sudden death during competition. Approximately 5%-10% of individuals with HCM progress to end-stage disease with impaired systolic function and, in some cases, left ventricular dilatation and regression of LVH. The annual mortality rate in individuals with end-stage disease is estimated at 11% and cardiac transplantation may be required. Current testing is estimated (depending on number of genes tested - from 10 to 31 genes) to detect a mutation in 60-80% of individuals with HCM. Most of the mutations are found in sarcomeric proteins that are involved with contraction of the heart muscle, but undiagnosed glycogen storage disease can also present as HCM, as can transthyretin amyloidosis; some panels include these genes. Approximately 5% of patients will have two or more mutations identified (compound heterozygote); these patients often have an earlier age of onset and worse prognosis.

HCM is typically diagnosed clinically with cardiac imaging, physical exam, electrocardiogram, or based on histopathologic features at autopsy. Among persons with clinically diagnosed HCM, genetic testing is of unclear benefit for risk stratification, specifically sudden cardiac death (SCD) (Gersh et al., AHA/ACC Guidelines, 2011). The major benefit of genetic testing in non-syndromic HCM lies in at-risk family member identification, prenatal testing, preimplantation genetic diagnosis, and, occasionally, distinguishing hereditary HCM from a secondary cause (e.g. uncontrolled hypertension, athlete's heart).

In the absence of an identifiable pathogenic mutation in the family, medical management for individuals with a family history of HCM includes increased cardiac screening with physical examination, 12-lead EKG, annual two-dimensional echocardiography during adolescence, and in some cases cardiac MRI, with screening continuing every 5 years in adulthood. Given the possibility for late-onset disease,

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2017 Informed Medical Decisions, Inc. All Rights Reserved.

screening well into adulthood is recommended. Once a mutation has been identified, testing negative for a known familial mutation allows at-risk family members to discontinue all screening (which can be both costly and time-consuming) (Gersh et al., AHHF/AHA Guidelines, 2011).

## Brugada Syndrome

The diagnosis of Brugada Syndrome (BrS) is based on symptoms, electrocardiogram (EKG) and family history. A diagnosis can be made based on EKG results and clinical history in approximately 75% of persons. Genetic testing can also be helpful to make a diagnosis of BrS.

BrS is characterized by a specific pattern of EKG (ST segment elevation in leads V1-V3). This can be associated with right bundle branch block, a defect in the heart's conduction system that can also be seen on EKG. This pattern may be seen on resting EKG or may require an EKG while receiving a drug known as a sodium channel blocker. Symptoms of BrS can include arrhythmia or irregular heartbeats and fainting spells. These symptoms often occur at rest. Other triggers include high fever, large meals and excessive alcohol consumption. These BrS symptoms may be fatal if untreated.

Brugada syndrome typically presents in males in their 30s or 40s and is the second cause of death in men from Southeast Asia under the age of 40 years. Implantable cardioverter defibrillators (ICDs) are the only therapy currently known to be effective in persons with BrS with syncope or cardiac arrest. Avoidance of certain medications is recommended for persons with Brugada syndrome, as well as particular attention during a febrile state as this can be a risk factor for syncope.

At least sixteen genes are associated with Brugada syndrome. However, a recent study did not find a significant association between mutations in genes other than SCN5A and arrhythmia in a European population and warns about interpretation of variants in such other genes (Le Scouarnec 2015). Mutations in the SCN5A gene are the most common genetic cause for Brugada syndrome (20-30%) and account for >75% of BrS genotype positive persons. Targeted testing of SCN5A can be useful among persons with clinical suspicion for BrS, according to HRS guidelines (2011). Genetic testing is not indicated among persons with an isolated type 2 or 3 Brugada pattern on EKG. In most cases, the primary value of genetic testing for Brugada syndrome is to benefit at-risk family members.

## Short QT Syndrome

Short QT syndrome (SQTS) is a congenital, inherited, primary electric disorder of the heart characterized by abnormally short QT intervals on the surface ECG (<360 ms) and an increased proclivity to develop atrial and/or ventricular tachyarrhythmias (Gussak 2005). SQTS is a genetically heterogeneous disease caused by mutations in five different genes (KCNH2, KCNQ1, KCNJ2, CACNA1C, and CACNB2B). All follow autosomal dominant inheritance; KCNH2 mutations are by far the most common cause in affected individuals (Patel 2010). However, mutation frequency and penetrance of these genes are uncertain.

HRS/EHRA guidelines regarding channelopathies and cardiomyopathies state that comprehensive or targeted SQTS genetic testing may be considered for any patient in whom a cardiologist has established a strong clinical index of suspicion for SQTS based on examination of the patient's clinical history, family history, and electrocardiographic phenotype (Class IIb-May be Useful) (HRS/EHRA 2011).

## Atrial Fibrillation

Atrial fibrillation is characterized by uncoordinated electrical activity in the atria. Symptoms include dizziness, chest pain, palpitations, shortness of breath, syncope and an increased risk of stroke and sudden death. Some individuals with atrial fibrillation do not experience any symptoms. While the

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2017 Informed Medical Decisions, Inc. All Rights Reserved.



majority of cases of AF are not hereditary, familial clustering does occur. Familial cases of AF are indistinguishable from acquired cases. Although a number of genes have been associated with an increased risk of AF, the role of these common genetic variants in risk stratification, assessment of disease progression, and determination of clinical outcomes is limited. Routine genetic testing related to AF is not indicated (January; ACC/AHA/HRS Practice Guidelines 2014).

## Post-Mortem Testing

When plans cover genetic testing for the benefit of family members, postmortem genetic testing to confirm a diagnosis and allow for early detection of other family members should be considered. Best practice guidelines describe appropriate testing scenarios that include young (<40) unexplained sudden death and cases of suspected cardiomyopathies. Recent evidence suggests that genetic testing can help identify inherited cardiac disease in 25-35% of cases of sudden cardiac deaths.

Examples of suspicious circumstances at the time of death include: drowning in an experienced swimmer, single motor vehicle accident when no other factors present (negative toxicology screen), unexplained seizure in young person and sudden death during exercise or sleep.

# Professional Society Guidelines

Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Heart Rhythm*. 2011 Aug;8(8):1308-39.

Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. *Circulation*. 2005 Feb 8;111(5):659-70.

Elliott PM, Anastakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J*. 2014 Oct 14;35(39):2733-79.

Gersh BJ, Maron BJ, Bonow RO, et al. ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Thorac Cardiovasc Surg*. 2011 Dec;142(6):e153-203.

Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. *J Card Fail*. 2009 Mar;15(2):83-97.

Hundley WG, Bluemke DA, Finn JP, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance. *J Am Coll Cardiol*. 2010 Jun 8;55(23):2614-62.

January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2014 Dec 2;64(21):e1-76.

Lehnart SE, Ackerman MJ, Benson DW Jr, et al. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping,

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2017 Informed Medical Decisions, Inc. All Rights Reserved.

molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. *Circulation*. 2007 Nov 13;116(20):2325-45.

Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. *Circulation*. 2007 Mar 27;115(12):1643-455.

## Selected References

- 1 Behr E, Wood DA, Wright M, et al. Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome. *Lancet*. 2003 Nov 1, 362(9394):1457-9.
- 2 Brugada R. Sudden death: managing the family, the role of genetics. *Heart*. 2011 Apr;97(8):676-81.
- 3 Clarke JL, Ladapo JL, Monane M, et al. The diagnosis of CAD in women: addressing the unmet need - a report from the national expert roundtable meeting. *Popul Health Manag*. 2015 Apr;18(2):86-92.
- 4 Crotti L, Celano G, Dagradi F, et al. Congenital long QT syndrome. *Orphanet J Rare Dis*. 2008 Jul 7;3:18.
- 5 Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. *J Am Coll Cardiol*. 2011;57:51-9.
- 6 Gussak I, Bjerregaard P. Short QT syndrome: 5 years of progress. *J Electrocardiol*. 2005 Oct;38(4):375-7.
- 7 Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? *Cardiology*. 2000;94(2):99-102.
- 8 Haas J, Frese KS, Peil B, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. *Eur Heart J*. 2015 May 7;36(18):1123-35a.
- 9 Le Scouarnec S, Karakachoff M, Gourraud JB, et al. Testing the burden of rare variation in arrhythmia-susceptibility genes provides new insights into molecular diagnosis for Brugada syndrome. *Hum Mol Genet*. 2015 May 15;24(10):2757-63.
- 10 Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. *J Am Coll Cardiol*. 2014 Apr 8;63(13):1300-8.
- 11 Mega JL, Stitzel NO, Smith JG et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. *Lancet*. 2015 Jun 6;385(9984):2264-71.
- 12 Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. *N Engl J Med*. 2006 Jan 12;354(2):209-10.
- 13 Middleton O, Baxter S, Demo E, et al. National Association of Medical Examiners position paper: retaining postmortem samples for genetic testing. *Acad Forensic Pathol* 2013;3(2):191-194.
- 14 National Society of Genetic Counselors [Internet]. Chicago, IL: National Society of Genetic Counselors; c2017. Post mortem genetic testing. [updated 2017 Aug; cited 13 Sep. 2017]. Available at: <http://www.nsgc.org/postmortem>.
- 15 Patel, C, Gan-Xin, Y, Antzelevitc, C. Short QT syndrome: from bench to bedside. *Circulation: Arrhythmia and Electrophysiology*. 2010;3:401-408.
- 16 Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. *JAMA*. 2005 Jan 26;293(4):447-54.
- 17 Schwartz PJ. The congenital long QT syndromes from genotype to phenotype: clinical implications. *J Intern Med*. 2006 Jan;259(1):39-47.
- 18 Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. *Circulation*. 2011 Nov 15;124(20):2181-4.
- 19 Tan HL, Hofman N, van Langen IM, et al. Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. *Circulation*. 2005 Jul 12;112(2):207-13.
- 20 van Langen IM, Birnie E, Alders M, et al. The use of genotype-phenotype correlations in mutation analysis for the long QT syndrome. *J Med Genet*. 2003;40:141-5.
- 21 van Berlo JH, de Voogt WG, van der Kooij AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? *J Mol Med (Berl)*. 2005 Jan;83(1):79-83
- 22 Waldmüller S, Schroeder C, Sturm M, et al. Targeted 46-gene and clinical exome sequencing for mutations causing cardiomyopathies. *Mol Cell Probes*. 2015 Oct;29(5):308-14.

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2017 Informed Medical Decisions, Inc. All Rights Reserved.

# Revision History

## Clinical Steering Committee Review:

v3.2017 09/20/2017: Approved

v2.2017 03/29/2017: Approved

v1.2017 01/25/2017: Approved

## Revisions:

Version	Date	Editor	Description
v3.2017	09/15/2017	Megan Czarniecki, MS, CGC	Revised general criteria language. Formatted references to NLM style. Moved methodological considerations to appropriate use criteria and background. Updated associated CPT codes. Renumbered to v3.2017 and submitted to CSC for approval.
v2.2017	06/19/2017	Kate Charyk, MS, CGC	Quarterly review. No criteria changes. Updated references.
v2.2017	04/21/2017	Kate Charyk, MS, CGC	Quarterly review. No criteria changes. Updated references.
v2.2017	03/29/2017	Kate Charyk, MS, CGC	Added criteria for post-mortem genetic testing. Updated references.
v1.2017	01/23/2017	Kate Charyk, MS, CGC	Quarterly review. No criteria changes. Updated references. Renumbered to 2017 version.
v1.2016	09/27/2016	Gwen Fraley, MS, CGC	Added general criteria. Updated references.
v1.2015	06/18/2015	Tricia See, MS, CGC	Original version

**Original Effective Date:** 06/18/2015

**Primary Author:** Tricia See, MS, CGC

PROPRIETARY

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2017 Informed Medical Decisions, Inc. All Rights Reserved.